| Home | |||
 |
|||
| CEO Message | |||
|
|||
| Questions & Answers On AI | |||
|
|||
| Avimex* Vaccines | |||
|
|||
| AI Videoconferences | |||
|
|||
| Technical Articles | |||
|
|||
| News | |||
|
|||
|
|||
| R&D | |||
|
|||
| Comments | |||
|
|||
 |
|||
|
|||
|
|||
 |
Passwords | ||
|
|||
| Login | |||
|
|
|||
 |
. | ||||
CEO Message |
|||||
|
|||||
About Avimex* Animal Health. Avimex* is an animal health-focused company that attends the needs of selected biological and pharmaceutical products of the poultry, swine, dairy cattle and shrimp industries in Mexico and in more than 25 countries around the world, including Africa, Asia, Central America, South America, East Europe and Middle East. Avimex* works under ISO-9000 and GMP standards in its Mexico City based production facilities, and devotes high quantity of its resources in R&D activities, including several alliances with well known Universities around the world. |
Shedd Off Program |
||||
|
|||||
| . | |||||
Avimex* Animal Health Obtains The Mexican License For NewH5®, Recombinant Vaccine Against Avian Influenza
Subtype H5 And Newcastle Disease. Mexico City, Mexico – January, 2008. Avimex*, the Mexican pharmaceutical company founded in 1952 and world-leader in killed avian influenza subtype H5 vaccine, and known for its innovative research and development activities focused on recombinant vaccines for poultry and swine, has announced by Dr. Bernardo Lozano - Avimex* CEO, that the company obtained at the end of 2007 the governmental license for NewH5® |
. | ||||
New H5 Recombinant Vaccine |
|||||
|
|||||
| see more | |||||
| ..www.avimex.com.mx | |||||
Avimex Avian Influenza Copyright © 2007, All rights reserved. ABOUT US